

Organized by



**Fondazione
Melanoma**

In collaboration with



Society for Immunotherapy of Cancer

Under the auspices of



ISTITUTO NAZIONALE TUMORI
IRCCS - Fondazione Pascale

IMMUNOTHERAPY ²⁰²⁵ BRIDGE

Naples (Italy)

December 3rd-4th, 2025

Royal Continental Hotel

Via Partenope 38-42

www.melanomabridge.org - info@melanomabridge.org

General Information

Congress venue

Royal Continental Hotel

Via Partenope 38-42, 80121 Naples



Registration

Registration fee: €880,00 + VAT 22%

Reduced registration fee for AIOM Members: €600,00 + VAT 22%

For information, registration and payments, please contact:

registration@melanomabridge.org

Confirmation of registration will be sent by the Organizing Secretariat.

Only registered participants will be admitted to the event.

» The registration fee includes:

- Participation in scientific sessions
- Congress kit (badge, notepad, pen)
- Coffee breaks and lunches

Official language

The official language is English.

Scientific Rational

Over the last years, an extensive research has improved our understanding of tumor immunology and enabled the development of novel treatments that can harness the patient's immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumors.

The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Study results have highlighted a number of recurring observations, including the immunotherapy potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The successes of the immune-oncology is strongly correlated with the immune system ability of "memory" and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapy drugs does not seem to be particularly influenced by histology and mutations.

First session of the congress will be jointly organized with the Society for ImmunoTherapy of Cancer (SITC).

Hence, the state of the art of Immunotherapy from the clinical point of view in various types of malignancies and the specific organ immune response, the novel cancer biology and its effects on immune cells and also the novel drugs beyond checkpoints, T-cell will be exhaustively discussed.

Then the "Great Debate" sessions, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view.

Conclusions will be drawn after the last session on Neoadjuvant therapies in different types of cancer.

Scientific Program

DAY 1 Wednesday, Dec 3rd

10.00 am Introduction and Objectives
Paolo A. Ascierto

SITC SESSION - NOVEL IMMUNE BIOLOGY

Chairpersons: **Leisha A. Emens, James L. Gulley**

10.10 am Novel Biology in T-cells
Tomas Kirchhoff

10.25 am Q&A

10.30 am Novel Biology in NK-cells
Eric Vivier

10.45 am Q&A

10.50 am Novel Biology in B-cells
Tullia Bruno

11.05 am Novel Biology in Myeloid cells
Jennifer Guerriero

11.20 am Translating preclinical myeloid biology into clinical trials
Thomas Marron

11.35 am Are neutrophils friends or foes in immunotherapy?
Brahm Segal vs Jennifer Guerriero

11.55 am Discussion

12.15 pm The best of SITC 2025
Paolo A. Ascierto

12.30 pm Q&A

12.35 pm LECTURE

Overview and current treatment landscape for head and neck squamous cell carcinoma

Robert L. Ferris

New frontiers in locally advanced HNSCC: hot to best integrate immunotherapy
Paolo Bossi

1.05 pm **Lunch****

GREAT DEBATE

Chairpersons: **Paolo A. Ascierto, Leisha A. Emens, Igor Puzanov**

2.00 pm Targeting T-cells vs NK-cells
Chrystal M. Paulos vs Timothy Lu

**Speakers to be confirmed*

*** Not included in the CME accredited program*

Scientific Program

DAY 1 Wednesday, Dec 3rd

2.25 pm Should we clone shared/public antigen TCRs or personalized neoantigen TCRs for patient therapy?
Michael V. Gormally vs Stephen Schoenberger

SESSION 2 - NOVEL CANCER BIOLOGY AND ITS EFFECTS ON IMMUNE CELLS

Chairpersons: **Alfredo Budillon, Luigi Buonaguro**

2.50 pm The interplay of oncogenic alterations with anti-tumor T cell responses
Sandra Demaria

3.05 pm Cancer cell aberration on T-cell function
Roberta Zappasodi

3.20 pm Epigenetic dysregulation
David Goodrich

3.35 pm Non-canonical epitopes
Bernard A. Fox

3.50 pm Cancer stem cells and immunity
Dean Tang

4.15 pm Discussion

4.45 pm **Coffee Break****

SESSION 3 - NOVEL DRUGS BEYOND CHECKPOINTS, T-CELL

Chairpersons: **Samir N. Khleif, Ignacio Melero**

5.00 pm Small molecules effect on immune system
Timothy Heffernan

5.15 pm Microbiome
Luigi Nezi

5.30 pm Targeting metabolism
Jennifer L. McQuade

5.45 pm Revisiting Cytokines and Beyond
Igor Puzanov

6.00 pm Discussion

**Speakers to be confirmed*

*** Not included in the CME accredited program*

Scientific Program

DAY 2 Thursday, Dec 4th

SESSION 4 - ORGAN SPECIFIC IMMUNE RESPONSE

Chairpersons: **Omid Hamid, Sandro Pignata**

- 9.30 am Liver
Bruno Daniele
- 9.40 am Bone Metastasis
Heathcliff Dorado Garcia*
- 9.50 am Brain Metastasis
Hussein Tawbi
- 10.00 am News in Lung Cancer
Alessandro Morabito
- 10.10 am GBM
Hideho Okada
- 10.20 am Pancreatic Cancer
Gregory B. Lesinski
- 10.30 am Colon Cancer MSS VS MSI
Myriam Chalabi*
- 10.40 am RCC
Toni K. Choueiri
- 10.50 am Rare Tumors
Andrew Futreal
- 11.00 am Discussion
- 11.30 am **Coffee Break****

GREAT DEBATE

Chairpersons: **Paolo A. Ascierto, Lisa H. Butterfield, Bernard A. Fox**

- 11.45 am Vaccines: Dark Matter vs Neo Antigens
Rom Leidner vs Stephen Schoenberger
- 12.10 pm Tertiary Lymphoid Structure Druggable Value: yes or no
Marco Donia vs Tullia Bruno
- 12.35 pm Combo-IO for every patient vs Precision Medicine
Tina Cascone vs Christian Rolf
- 1.00 pm **Lunch****

**Speakers to be confirmed*

*** Not included in the CME accredited program*

Scientific Program

DAY 2 Thursday, Dec 4th

2.00 pm **CME SYMPOSIUM - Non-Melanoma Skin Cancers**
The treatment of CSCC and BCC: an update
Paolo A. Ascierto, Dirk Schadendorf

SESSION 5 - NEOADJUVANT THERAPY ACROSS CANCERS

Chairpersons: **Paolo A. Ascierto, Elizabeth M. Burton**

2.50 pm INNOVATE summary
Paolo A. Ascierto

3.05 pm Breast
Leisha A. Emens

3.20 pm Lung
Tina Cascone

3.35 pm Melanoma
Christian Blank

3.50 pm Non Melanoma Skin Cancers, BCC and CSCC
Neil D. Gross

4.05 pm Neoadjuvant LAG3 translational insights
Elizabeth M. Burton

4.20 pm Pan tumor path response assessment
Julie Stein Deutsch

4.35 pm Discussion

5.05 pm Conclusion
Paolo A. Ascierto, Leisha A. Emens, Bernard A. Fox, James L. Gulley, Igor Puzanov

**Speakers to be confirmed*

*** Not included in the CME accredited program*

Presidency



Paolo A. Ascierto

Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione "G. Pascale", Naples, Italy



Leisha A. Emens

Senior Vice President Translational Research, Ankyra Therapeutics, Incorporated, Boston, MA, US; Past President of Society for Immunotherapy of Cancer (SITC)



Bernard A. Fox

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Center Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US



James L. Gulley

Co-Director of the Center for Immuno-Oncology, Center for Cancer Research (CCR), the National Cancer Institute (NCI), Bethesda, MD, US; President of Society for Immunotherapy of Cancer (SITC)



Igor Puzanov

Judith and Sanford Lipsey Chair in Clinical Cancer Research; Senior Vice President, Clinical Investigation Chief, Division of Melanoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

Scientific Board

Sanjiv S. Agarwala

Professor of Hematology & Oncology, Temple University School of Medicine, Philadelphia, PA, US

Paolo A. Ascierto

Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute IRCCS Fondazione "G. Pascale", Naples, Italy

Carlo Bifulco

Chief Medical Officer, Providence Genomics, Director of Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Scientific Board

Christian Blank

Medical Oncology and Research Group Leader Tumor Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

Elizabeth M. Burton

Executive Director, Translational Research Initiative Development, Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, US

Lisa H. Butterfield

Ph.D., Distinguished Scientist Discovery Oncology, Merck Research Labs, South San Francisco, CA, US

Corrado Caracò

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute, IRCCS Fondazione "G. Pascale", Naples, Italy

Mary Dean

Executive Director, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

Sandra Demaria

Professor of Radiation Oncology, Professor of Pathology and Laboratory Medicine Weill Cornell Medicine, New York, NY, US

Reinhard Dummer

Vice Director, Department of Dermatology; Director, Clinical Trials Comprehensive Cancer Center Zurich (CCCZ), University Hospital Zurich, Zurich, Switzerland

Alexander M.M. Eggermont

Chief Scientific Officer, Board of Directors, Princess Máxima Center; Professor of Clinical&Translational Immunotherapy, Utrecht University, Utrecht, Netherlands

Leisha A. Emens

Senior Vice President Translational Research, Ankyra Therapeutics, Incorporated, Boston, MA, US; Past President of Society for Immunotherapy of Cancer (SITC)

Bernard A. Fox

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Center Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Jerome Galon

Research Director, National Institute of Health and Medical Research (INSERM), Director, Integrative Cancer Immunology Team, Cordeliers Research Center, Paris, France

Scientific Board

Jeffrey E. Gershenwald

Dr. John M. Skibber Endowed Professor of Surgery, Department of Surgical Oncology, Medical Director, Melanoma and Skin Center, The University of Texas, MD Anderson Cancer Center, Distinguished Senior Lecturer, The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, Houston, TX, USA

James L. Gulley

Co-Director of the Center for Immuno-Oncology, Center for Cancer Research (CCR), the National Cancer Institute (NCI), Bethesda, MD, US; President of Society for Immunotherapy of Cancer (SITC)

Omid Hamid

Chief of Research/ Immuno-Oncology, Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA, US

Samir N. Khleif

Director of Center for Immunology and Immunotherapy, Director of The Loop Immuno-Oncology Laboratory, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, US

Giuseppe Masucci

Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

Olivier Michielin

Full Professor, Chair of Oncology Department and Precision Oncology Service, Geneva University Hospital, Geneva; Co-Director of the Swiss Cancer Center Léman, Agora - Lausanne, Switzerland

Iman Osman

Rudolf Baer Professor of Dermatology Professor, Departments of Medicine (Oncology) and Urology Director, NYU Melanoma SPORE Associate Dean for Clinical Research Strategy NYU Grossman School of Medicine, New York, NY, US

Giuseppe Palmieri

Full Professor of Medical Oncology, University of Sassari; Immuno-Oncology & Targeted Cancer Biotherapies, Sassari University Hospital; Associate Researcher, Head of Unit of Cancer Genetics, National Research Council (CNR); Head, Institute of Genetic & Biomedical Research (IRGB), Sassari, Italy

Michael A. Postow

Chief Melanoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, US

Scientific Board

Igor Puzanov

Judith and Sanford Lipsey Chair in Clinical Cancer Research; Senior Vice President, Clinical Investigation Chief, Division of Melanoma, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

Dirk Schadendorf

Director of the Department of Dermatology, University Hospital Essen, Essen, Germany

Magdalena Thurin

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, US

Tara Withington

Executive Director Emeritus, Society for Immunotherapy of Cancer (SITC), Milwaukee, WI, US

CONTINUING MEDICAL EDUCATION

CME Credits

CME Code: 596-464558 Ed.1

The course has been accredited with 3.6 CME credits.

To obtain CME credits, participants must attend at least 90% of the total course duration and complete the event evaluation.

National Objective:

Technical and professional content (knowledge and skills) specific to each profession, specialization, and ultra specialized activity, including rare diseases and gender medicine.

Target Audience:

This course is intended at 201 participants among the following professions:

- Pharmacists
- Biologists
- Medical Doctors specializing in:
Allergology and Clinical Immunology, Dermatology and Venereology, Hematology, Gastroenterology, Respiratory diseases, Internal Medicine, Nephrology, Neurology, Oncology, Radiotherapy, General Surgery, Plastic and Reconstructive Surgery, Gynecology and Obstetrics, Urology, Pathological Anatomy, Clinical Pharmacology and Toxicology, Medical Genetics Laboratory, Nuclear Medicine, Clinical Pathology (Chemical-Clinical Laboratory and Microbiology), Radio diagnostics, Hygiene, Epidemiology, and Public Health, General Medicine (General Practitioners), Nutrition Science and Dietetics, Palliative Care
- Pediatric Nurses
- Nurses

CME Provider

OPT S.p.a.

Via Mauro Macchi 38, 20124 Milano
www.optsalute.it



Organizing Secretariat

Vivenko Srl Società Benefit

Via De Amicis 42, 20123 Milan, Italy
www.vivenko.net
info@melanomabridge.org

